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Abstract 
Purpose: To undertake an in silico assessment of rocaglamide as a potential drug therapy for 
periodontitis (dental arthritis). 
Method: Lamarckian algorithm-based automated docking approach using AutoDock4.2 tool was 
applied for calculating the best possible binding mode of rocaglamide to IL-23p19 and IL-17, the targets 
of anti-inflammatory drugs in periodontal disease.  
Results: The top two interactions of rocaglamide with IL-17 (ΔG = -5.45 and -4.83 kcal/mol) were more 
spontaneous, and the physical interactions (two hydrogen bonds and one π-πbond) generated in the 
two IL-17- rocaglamide complexes were higher in number than in IL-23p14-rocaglamide complexes. 
Conclusion: In silico analysis of rocaglamide, a known antimicrobial and anti-inflammatory agent, is a 
promising natural candidate for periodontitis therapy, and should be further subjected to in vitro and in 
vivo anti-periodontitis investigations. 
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 Periodontal disease or periodontitisis is a 
chronic, bacterial infection-associated auto-
immune disease characterized by anomaly in the 
teeth-supporting structure, tissue destruction and 
bone loss [1]. Some of the bacterial pathogens 
involved in the infection leading to periodontitis 
are Bacteroides gingivalis, Bacteroides 
intermedius and Actinobacillus actinomycete-
mcomitans [2]. The autoimmune basis of this 
disease was first postulated nearly fifty years ago 
by Brandtzaeg and Kraus [3]. The innate immune 
system has a general role against bacterial 
pathogens [4,5]. Indeed, it is the subsequent 
inflammatory and immune processes associated 
with the bacterial pathogens that are harmful to 
the host and contribute to the tissue injury 
observed in periodontitis [6]. Cell-mediated 
immune response plays a pathological role in 
many inflammatory diseases [7]. 
 
In periodontitis, the host mechanism is complex, 
as it involves both protective and destructive 
elements, which are characterized by immune-
inflammatory response to the pathogen and 
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subsequent destruction in the teeth-supporting 
structure by autoimmune response [8,9]. Several 
studies have associated Th1 and Th2 with the 
etiology of periodontitis [10-14]. Th1 and Th2 are 
the important components of the immune 
response which are associated with inflammatory 
disease and allergic reaction, respectively. Th1 
cells and its cytokines are associated with early 
periodontal lesions, while Th2 and its cytokines 
are associated with periodontitis progression [10-
14]. 
 
The number of anti-cytokine drugs targeting 
inflammatory cytokines against IL-1b, IL-12p40, 
IL-6, IL-23p19 and IL-17 has increased 
significantly [15]. The first three cytokine targets 
(IL-1b, IL-12p40 and IL-60) are the most 
frequently drug-targeted cytokines, while IL-
23p19 and IL-17 are relatively new targets. The 
objective of the present study was to use 
Computer-Aided Drug Design (CADD) to study 
the effectiveness of rocaglamide, a known 
antimicrobial and anti-inflammatory agent [16], as 
an anti-periodontitis agent. For this purpose, 
CADD, which has become a promising tool in 
new drug discovery [17], was used to target IL-






The x-ray-crystallographic structures of IL-23p19 
and IL-17 proteins were retrieved from PDB 
(http://www.pdb.org/). The crystallographic 
structure of IL-23p19 protein which contains 189 
amino acids bearing PDB ID: 4GRW, was 
retrieved and modified accordingly by removal of 
unwanted atoms and molecules to suit the 
molecular docking experiment. The IL-17 protein 
contains 155 amino acids and its crystallographic 





Rocaglamide, a natural compound was retrieved 
from PubChem compound database. The SDF 
format of the compound was retrieved bearing 
CID 331783, and it was converted to PDF prior to 
further studies, using Discovery Studio. 
 
Molecular docking analysis 
 
Molecular docking analysis of the IL-23p19 and 
IL-17 proteins with rocaglamide was done using 
Auto Dock4.2tool [19]. The Auto Dock4.2tool 
calculates energy values by classification of 
energies as internal energy and torsional free 
energy as in Eq 1. 
ΔG = ΔGvdw + ΔGH-bond + ΔGelec + ΔGtor + ΔGdesolv 
……….. (1) 
 
where ΔG represents the overall binding energy, 
while ΔGH-bond, ΔGelec and ΔGtor represent 
hydrogen bonding, electrostatic bonding and 
translation/rotation energies, respectively. The 
term ΔGdesolv indicates the desolvation energy on 
binding and hydrophobic effect. Lamarckian 
genetic algorithm (GA) default parameters were 
used for calculating ∆G of each shortlisted 
compound. Grid box (60 × 60 × 60 A°) was built 
around the active site. Five top interactions out of 
ten were studied for each protein. All the 





The pathway interaction profile of IL-17A and IL-
23A (IL-23p19) derived using Gene Mania 
database (web-based integrative software) 
generated the network architecture of the 
connections of the two cytokines and other 
important proteins, as shown in Figure 1. The 
generated protein network were proteins 
commonly involved in auto-immune diseases 
such as rheumatoid arthritis. This confirms the 





Figure 1: Protein sub-networks of IL-17A and IL-23A 
(queried proteins) with IL-6, NFKB1A and some 
important proteins involved in arthritis (only significant 
sub-networks are shown) 
 
The 3D structure of the protein retrieved from 
protein database was trimmed to suit the 
experimental design using Discovery studio. The 
modification of both proteins are shown Figure 
2a (IL-23p19) and Figure 2b (IL-17). The trimmed 
structures were used for molecular docking, and 
blind docking approach was used to look into the 
possibility of successful docking of rocaglamide 
onto the two selected cytokines. Table 1 shows 
the Gibbs free energy of the top two poses of 
each complex. 
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Figure 2: The original crystallographic structure of the 
protein available and the trimmed protein used for the 
study. (a) The trimmed structure represents IL-23p14 
protein from amino acid 8-168 (b) The second 
structure represents amino acids 35- 128 of IL-17 
 
Table 1: Gibbs free energy of top two poses of 






1 -1.54 -5.45 
2 -0.64 -4.83 
 
The best poses of both protein-drug complexes 
are shown in Figure 3. Table 2 shows the top two 
interactions of the drug with each protein. The 
protein-drug interaction (covalent or non-
covalent), and the number of hydrogen bonds 
formed by both proteins with the drug are 
displayed in Figure 4, where 4(a) represents IL-
23p14, and 4(b) represents IL-17.  
 
The only interaction formed by rocaglamide and 
IL-23p14 was the pi-pi interaction as shown in 
Figure 5 (a), the binding pocket in this pose was 
TRP26, LEU31, ARG148, GLN151, ALA152, 
ALA155, VAL156 and ARG159. Figure 5 (b) 




Figure 3:  The two best poses of rocaglamide with (a) 
IL-23p14 and (b) IL-17 
 
 
Figure 4: The three dimensional representation of the 
top two poses of rocaglamide. The top two interactions 
of IL-23p14 and rocaglamide had ΔG values of -1.54 




Rocaglamide formed better interactions with IL-
17. The top pose had a ΔG of -5.45 kcal/mol, and 
exhibited two hydrogen bond interactions with 
TYR-44 andVAL-119 in the binding pocket. The 
binding pocket of IL-17 for rocaglamide 
contained the following amino acids: PRO-37, 
Table 2: Auto dock analysis of the top two poses of protein-rocaglamide complexes. 
 
Cytokine Rank Ligand binding pocket H-bond 
 
IL-23p14 
1 TRP26, LEU31, ARG148, GLN151, ALA152, ALA155, VAL156, ARG159 pi-pi interaction withARG159 






PRO37, LYS38, SER41, TYR43, TYR44, 
SER47, TRP51, LEU53, ILE92, VAL119, 
GLY120, CYS121 
Two pi-pi interactions withTRP51 
One Hydrogen bond with 
VAL119 
One Hydrogen bond with TYR44 
 
2 THR35, PRO37, LYS38, SER40, SER41, TYR44, TRP51, VAL119,GLY120 
pi-pi interaction withTRP51 
One Hydrogen bond with TRP51 
One Hydrogen bond with SER40 
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Figure 5: Two dimensional representations of the top 
four poses. (a) and (b) show the top two poses of IL-
23p14, while (c) and (d) show IL-17 interactions with 
rocaglamide 
 
LYS-38, SER-41, TYR-43, TYR-44, SER-47, 
TRP-51, LEU-53, ILE-92, VAL-119, GLY-120, 
and CYS-121. Two rocaglamide atoms, O-6 and 
H-41formed bond with TYR-44 andVAL-119, 
respectively with bond lengths of 3.16 and 2.29 
Ǻ, respectively. Rather than forming two 
hydrogen bond interactions, the complex 
rocaglamide-IL-17 complex exhibited two pi-pi 
interactions, as shown in Figure 5 (c). The 
second best pose of IL-17 in the rocaglamide-IL-
17 complex had a ΔG of -4.83 kcal/mol. It also 
exhibited two hydrogen bond interactions in the 
binding pocket. The binding pocket in this case 
contained the following amino acids: THR-35, 
PRO-37, LYS-38, SER-40, SER-41, TYR-44, 
TRP-51, VAL-119 and GLY-120.The O-6and O-
7atoms of rocaglamide interacted with SER-40 
and TRP-51, with bond lengths of 2.7 and 2.8 Ǻ, 
respectively. Based on binding energies, 
rocaglamide showed the least binding energy of -
0.63kcal/mole with IL-23p14. 
 
Various conceptual models spanning over five 
decades have been proposed to describe the 
etiology of periodontitis. Two factors, microbial 
infection and inflammation, are thought to play 
pivotal roles in the shift from the healthy state to 
periodontitis. Thus, the development of strategies 
is based on these two factors. Compounds of 
natural origin are invaluable in novel drug 
discovery, and many natural compounds have 
been reported to have dual functions [17,20]. The 
present study was focused on a compound with 
antimicrobial and anti-inflammatory properties. 
This was based on knowledge from Traditional 
Chinese Medicine. Rocaglamide, a flavagline of 
natural origin, is a known traditional Chinese 
medicinal compound with antimicrobial and anti-
inflammatory activities. However, the mechanism 
of action of rocaglamide is yet to be ascertained. 
It is well established that CADD is an important 
route for investigating the possible mode of 
action of drugs. The present study has explored 
possible targets in the inflammatory pathway that 
rocaglamide can act on. The data generated 
here will be useful in developing more robust 





The results obtained in this study suggest that 
rocaglamide may have potent anti-periodontitis 
effects. Being an anti-inflammatory drug with 
known anti-microbial activity, these findings 
make it potentially suitable for the development 
of a new drug for treating periodontitis, a disease 
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